Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Computational biologists develop program for easy diagnosis of hereditary illnesses

In the case of a cough or a sore throat, the doctor can usually diagnose a common cold immediately. However, the diagnosis of hereditary illnesses like cystic fibrosis, which affects the metabolism, or Huntington's disease, which leads to cognitive decline, is much more complex.

29 Jul 2014

NC Senate plan to overhaul state Medicaid program draws fire from doctors and hospitals

The North Carolina plan was presented by state senators during a Wednesday meeting of the Senate Rules and Operations Committee.

18 Jul 2014

First Edition: July 17, 2014

Today's headlines include reports about how Capitol Hill politics are impacting health care policy. Houston Public Media's Carrie Feibel, working in partnership with Kaiser Health News and NPR, reports: "Primary care doctors have reported problems making referrals for patients who have purchased some of the cheaper plans from the federal insurance marketplace.

17 Jul 2014

PTC Therapeutics initiates reimbursed expanded access program for Translarna

PTC Therapeutics, Inc. today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna (ataluren) available to patients before commercial availability in certain countries.

9 Jul 2014

Children who undergo simple emergency surgeries on weekends are more likely to die

Children who undergo simple emergency surgeries, such as hernia repairs or appendix removals, on weekends are more likely to suffer complications and even die than children getting the same kind of treatment during the week, according to results of a Johns Hopkins Children's Center study.

1 Jul 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Queen's doctor plays key role in major breakthrough to change lives of cystic fibrosis sufferers

A Queen's University doctor has played a key role in a major breakthrough to change the lives of cystic fibrosis sufferers.

26 Jun 2014

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Forest Laboratories, Inc. today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD).

24 Jun 2014

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).

23 Jun 2014

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care.

9 Jun 2014

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm Corporation is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.

9 Jun 2014

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and  Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.

2 Jun 2014

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet.

31 May 2014

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

PTC Therapeutics, Inc. today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.

23 May 2014

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).

20 May 2014

Study shows technology improves transition into adulthood for adolescents with chronic disease

Adolescents with chronic diseases (ACD), such as cystic fibrosis, gastrointestinal disorders (including Crohn's disease) and Type 1 diabetes, often find the transition of managing their health care needs into adulthood to be challenging.

19 May 2014

Aradigm reports total revenue of $6.6 million for Q1 2014

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2014.

14 May 2014

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

We were extremely excited to launch the Impact 2020 report at our annual meeting. Our five-year strategic plan is focused on value, early-stage financing and ensuring more patient-centered discussions.

5 May 2014

FDA approves Parion’s investigational new drug application for treatment of dry eye disease

Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.

2 May 2014

Vertex: Conditions of PBAC recommendation may limit Australians who could benefit from KALYDECO

The Pharmaceutical Benefits Advisory Committee has again recommended KALYDECO (ivacaftor) for listing on the Pharmaceutical Benefits Scheme (PBS). However, Vertex is deeply disappointed in the conditions the PBAC has attached to the recommendation. These conditions fail to reflect the substantial clinical benefits recognised by the PBAC, and would result in limiting the number of eligible Australians who would be able to receive KALYDECO.

30 Apr 2014

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Computational biologists develop program for easy diagnosis of hereditary illnesses

NC Senate plan to overhaul state Medicaid program draws fire from doctors and hospitals

First Edition: July 17, 2014

PTC Therapeutics initiates reimbursed expanded access program for Translarna

Children who undergo simple emergency surgeries on weekends are more likely to die

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Queen's doctor plays key role in major breakthrough to change lives of cystic fibrosis sufferers

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Celsus’ expert highlights serious side effects of topical corticosteroids

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Study shows technology improves transition into adulthood for adolescents with chronic disease

Aradigm reports total revenue of $6.6 million for Q1 2014

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

FDA approves Parion’s investigational new drug application for treatment of dry eye disease

Vertex: Conditions of PBAC recommendation may limit Australians who could benefit from KALYDECO

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in